Arkadios Wealth Advisors Has $1.46 Million Stock Holdings in Omnicell, Inc. $OMCL

Arkadios Wealth Advisors grew its position in Omnicell, Inc. (NASDAQ:OMCL) by 6.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,791 shares of the company’s stock after acquiring an additional 3,086 shares during the quarter. Arkadios Wealth Advisors owned 0.11% of Omnicell worth $1,464,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in shares of Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock valued at $58,745,000 after purchasing an additional 154,038 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 1.3% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after buying an additional 17,680 shares during the period. Wellington Management Group LLP increased its holdings in Omnicell by 52.6% in the 1st quarter. Wellington Management Group LLP now owns 496,680 shares of the company’s stock valued at $17,364,000 after buying an additional 171,116 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Omnicell by 5.7% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 453,988 shares of the company’s stock valued at $15,871,000 after buying an additional 24,301 shares during the period. Finally, Pacer Advisors Inc. bought a new stake in Omnicell in the 1st quarter valued at $10,542,000. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, July 21st. Piper Sandler dropped their target price on Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 11th. Benchmark increased their target price on Omnicell from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $42.00.

Omnicell Price Performance

OMCL opened at $33.57 on Friday. The company’s 50 day simple moving average is $31.36 and its 200-day simple moving average is $30.19. Omnicell, Inc. has a one year low of $22.66 and a one year high of $53.31. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock has a market capitalization of $1.54 billion, a P/E ratio of 67.14, a price-to-earnings-growth ratio of 6.29 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.15. The firm had revenue of $310.63 million for the quarter, compared to the consensus estimate of $295.59 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. Omnicell has set its FY 2025 guidance at 1.630-1.730 EPS. Q4 2025 guidance at 0.400-0.500 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 3,880 shares of Omnicell stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares in the company, valued at $3,679,212.25. This trade represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.52% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.